Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients
Phase 3
Completed
- Conditions
- Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
- Interventions
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 106
- Registration Number
- NCT01544491
- Locations
- 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom
Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 71
- Registration Number
- NCT01543854
- Locations
- 🇷🇺
Novartis Investigative Site, Tomsk, Russian Federation
Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2013-05-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT01543828
- Locations
- 🇺🇸
Novartis Investigative Site, Tacoma, Washington, United States
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
Not Applicable
Completed
- Conditions
- Age Related Macular Degeneration (AMD)
- Interventions
- Other: Health Management Tool (HMT)
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2018-07-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT01542866
- Locations
- 🇺🇸
Novartis Investigative Site, San Antonio, Texas, United States
Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)
- First Posted Date
- 2012-03-01
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3091
- Registration Number
- NCT01541956
- Locations
- 🇨🇳
Novartis Investigative Site, Beijing, China
Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.
- First Posted Date
- 2012-02-29
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT01541189
- Locations
- 🇨🇳
Novartis Investigative Site, Beijing, Beijing, China
Pharmacokinetics and Pharmacodynamics of BCT194 in Psoriatic Patients
- First Posted Date
- 2012-02-28
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT01539915
- Locations
- 🇦🇹
Novartis Investigative Site, Graz, Austria
Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT01539213
- Locations
- 🇦🇹
Novartis Investigative Site, Graz, Austria
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase 2
Completed
- Conditions
- Psoriasis, Plaque-type Psoriasis
- Interventions
- Drug: placebo
- First Posted Date
- 2012-02-23
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT01537432
- Locations
- 🇺🇸
Novartis Investigative Site, Norfolk, Virginia, United States
Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)
Phase 2
Completed
- Conditions
- Neovascular Age-elated Macular Degeneration (Wet AMD)Exudative Macular Degeneration
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-02-20
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT01535950
- Locations
- 🇺🇸
Novartis Investigative Site, Fort Worth, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath